HEAL Initiative: Optimization of Therapeutic Medical Devices through Team Science Mechanistic Research (RM1)

The HEAL Initiative’s "Optimization of Therapeutic Medical Devices through Team Science Mechanistic Research (RM1)" is an upcoming funding opportunity offered by the National Institutes of Health (NIH), specifically through the National Institute of Neurological Disorders and Stroke (NINDS). This initiative aims to improve the clinical impact of therapeutic medical devices by supporting research focused on understanding the mechanisms through which these devices exert their therapeutic effects. Many devices currently in clinical use or development have demonstrated inconsistent outcomes or have failed to translate successfully from preclinical models to human applications. By addressing this gap, the HEAL Initiative hopes to enhance device efficacy, inspire novel design, and support better health outcomes for patients using these therapies. The program encourages applications from interdisciplinary research teams with diverse expertise, including but not limited to biomedical engineering, neuroscience, surgery, clinical care, computational modeling, artificial intelligence, and regulatory science. These teams will be expected to pursue mechanistic investigations of both investigational and FDA-approved medical devices. Projects may include clinical studies, preclinical trials, and advanced computational simulations aimed at revealing how devices interact with human physiology and identifying biomarkers relevant to neurological disorders. This strategic research focus aligns with the broader goals of the HEAL Initiative, which seeks to develop and optimize non-opioid pain treatments and other interventions for neurological and chronic pain conditions. Funded research must have a clear trajectory toward improving or optimizing therapeutic devices for patient use. NIH emphasizes that strategies proposed under this program should be capable of meaningfully improving therapeutic outcomes. This includes identifying physiological targets, evaluating treatment efficacy, and optimizing device design or parameters based on new mechanistic insights. The funding opportunity supports not only the development of new devices but also efforts to refine and improve existing technologies already in use. The emphasis on team science underscores NIH’s recognition of the complexity of device mechanisms and the need for cross-disciplinary approaches. Although detailed application instructions have not yet been released, applicants should anticipate standard NIH submission processes via Grants.gov. At present, this is a forecasted opportunity, which means the application portal is not yet open. The forecast estimates a posting date of June 11, 2026, with full applications due by October 30, 2026. Awards are projected to be made by July 1, 2027, which also serves as the estimated project start date. Given the timeline, interested applicants are encouraged to begin forming interdisciplinary collaborations and preparing research plans in alignment with the goals of the initiative. Eligibility for this opportunity is expansive and includes a wide variety of organizations. Eligible applicants encompass public and private institutions of higher education, state, county, city, and township governments, federally recognized and non-federally recognized tribal governments and organizations, nonprofits with and without 501(c)(3) status, for-profit organizations including small businesses, public housing authorities, special district governments, U.S. territories and possessions, and non-U.S. institutions. Faith-based and community-based organizations and federal agencies may also apply. This broad eligibility reflects NIH’s intent to attract a wide array of expertise and perspectives to advance device-based therapeutic strategies. Applicants will be expected to address criteria such as scientific rationale, significance of the therapeutic mechanism under study, qualifications and synergy of the interdisciplinary team, and the potential translational value of their findings. NIH encourages early engagement with program officials to refine project ideas and ensure alignment with program goals. While no pre-application steps such as letters of intent are currently required, this may change once the official Notice of Funding Opportunity (NOFO) is published. All inquiries can be directed to the NINDS Translational Devices Team via [email protected].